Clinical Trial Update: Post Marketing Surveillance Study on Emselex After Launch in Germany

View source ↗

Summary

A completed post-marketing surveillance study of Emselex (mirabegron) conducted in Germany to monitor safety after its launch for overactive bladder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Emselex (darifenacin hydrobromide)

Snippet

Sponsor: Bayer | Conditions: Overactive Bladder | Status: COMPLETED